- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Platelet-rich fibrin reduces pain and accelerates healing of oral ulcers in blistering skin diseases
Platelet-rich fibrin (PRF) provides rapid pain reduction and accelerated healing of oral ulcers and hence is superior compared to corticosteroids, says a study published in Wound Repair and Regeneration.
The study was conducted by Eman M. Ahmed, Faculty of Dentistry, Beni-Suef University, Beni-Suef, Egypt, and colleagues with the objective to evaluate the healing power of platelet-rich fibrin in terms of pain control and mucosal repair.
For this purpose, the researchers conducted a randomized, controlled, pilot clinical trial on 16 patients. They were randomly distributed with a 1:1 allocation ratio into two groups. The treatment group received PRF minced and mixed with orabase and the control group received clobetasol propionate 0.05% mixed with orabase.
The study led to the following findings:
- Pain reduction was evaluated as the primary outcome along with mucositis healing as the secondary outcome.
- A statistically significant difference in pain reduction was observed between the two groups.
- The clinical results on Day 7 have shown that the PRF group had 100% pain reduction while CP group had a 32.5% reduction from baseline.
The researchers conclude, "PRF offered superior clinical results providing rapid pain alleviation and accelerated ulcer healing compared to corticosteroids."
What is platelet-rich fibrin (PRF)?
Platelet-rich fibrin (PRF) is a fibrin matrix in which growth factors, platelet cytokines, and cells are trapped and may be released after a certain time and that can serve as a resorbable membrane. It accelerates the healing of soft and hard tissue and is used as a tissue-engineering scaffold for endodontics. For obtaining PRF, a required blood quantity is dawn quickly into test tubes without an anticoagulant and centrifuged immediately.
Reference:
Ahmed EM, Shafik S, El Saadany B. Platelet-rich fibrin a new approach in management of persistent oral ulcers in blistering skin diseases. Wound Repair Regen. 2022 May 19. doi: 10.1111/wrr.13020. Epub ahead of print. PMID: 35589608.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751